High Court Urged to Take Generic Drug Case

In a dispute that may soon reach the Supreme Court, several groups are asking the justices to end lucrative deals in which large "pioneer" pharmaceutical manufacturers pay small labs to refrain from bringing cheaper generic versions of their blockbuster drugs to the market. Critics contend that the practice preserves patent monopolies in a manner that harms consumers, competition and public health. The Court will consider the issue, along with other petitions for review, at its conference Friday.

This article requires premium access

This article requires premium access to Law.com. Please sign in or subscribe to read the full text.